The story · written by gpt-6,
Jordan issued rules in 2023 for approving CBD natural medicines and preparations containing no more than 0.3% THC and dispensing them on a valid medical prescription. The instructions also set controls for imports, manufacturing, external-use cosmetics and medical devices.
Product rules followed changes to the drug law
The 2021 amendment had broadened first-offence record protection and added authority to license controlled plants and seeds under regulations. Medical and scientific handling already depended on official authorisation under the wider drug law.
Health Minister Firas Hawari signed the 2023 instructions under medicines and food-and-drug legislation. They supplied detailed conditions for handling CBD preparations, extracts and oils containing no more than 0.3% delta-9 THC.
The rules separated products by their intended use. A natural medicine made a direct treatment claim; a natural preparation fell under a different product definition. A classification committee determined the responsible regulatory directorate and approval route.
Approval required evidence about quality and manufacture
Applicants for natural preparations had to meet the existing natural-product requirements. The instructions also required approval of the active-ingredient manufacturer, specifications, an analysis certificate and a validated testing method.
Stability evidence formed part of the application, including accelerated testing over six months and available long-term results for two batches. These conditions connected the CBD route to medicine-quality assessment and the identity of the manufacturer.
For patients, the dispensing condition was a valid medical prescription. The instructions linked prescriptions to the existing requirements for their form and records.
Imports and external-use products had separate requirements
Importing or exporting the medical natural products required an invoice stamped by the regulator’s controlled-substances section. Medical raw materials were also subject to invoice controls.
Cosmetics and medical devices had their own conditions. Manufacturers had to use the relevant approvals for raw materials and report quantities, sales and buyers annually. Cosmetic and device manufacture under these instructions was restricted to external use.
Finished external-use cosmetics and devices in a form unsuitable for abuse were exempt from a separate controlled-substances import or export approval. Their product classification and the other regulatory requirements still governed the route to sale.
CBD regulation also reached food products
The same instructions permitted specified hemp seed foods under separate THC limits and labelling conditions.
The regulator’s September 2026 schedules exclude CBD-dominant oils, extracts and preparations containing no more than 0.3% THC from the controlled-drug tables. Product approval and prescription requirements continue to define the medical CBD route within Jordan’s wider cannabis rules.[1][2][3]
Listed for context. No score change is recorded for Jordan here.
References
- Jordan Food and Drug Administration — instructions 1 of 2023 for CBD and low-THC preparations, extracts and oilsOfficial Gazette 5844, printed pages 912–916: articles 1–9 and annex 1; all five facsimile pages visually readarchived
- Jordan Food and Drug Administration — Narcotic Drugs and Psychotropic Substances Law 23 of 2016, with amendmentsArticles 2–6, 9, 15, 19–20 and 39; final publication and commencement notes for the 2016 law and 2021 amendmentarchived
- Jordan Food and Drug Administration — controlled drug schedules, updated 30 September 2026PDF page 2, table 1: cannabis resin, extracts and tinctures; page 8, table 3: cannabis plant and CBD-dominant preparations, with the 0.3% THC exclusionarchived
Checked. The date and the event were compared with a source that was read.